TRIM34: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: TRIM34

NCBI ID: G53840

TRIM34

TRIM34: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide. It is characterized by a gradual accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain, leading to a range of symptoms such as memory loss, cognitive decline, and difficulty with daily activities. Despite the availability of disease-modifying therapies, there is currently no cure for Alzheimer's disease, and the majority of patients eventually develop irreversible cognitive impairments.

TRIM34, a protein that is expressed in the brains of individuals with Alzheimer's disease, has been identified as a potential drug target and biomarker for this disease. By targeting TRIM34, researchers may be able to reduce the formation of beta-amyloid plaques and neurofibrillary tangles, which could potentially slow the progression of Alzheimer's disease.

TRIM34 is a protein that is expressed in the brains of individuals with Alzheimer's disease, as well as in other neurodegenerative diseases. It is a part of a family of proteins called TRIM proteins, which are involved in the regulation of cellular processes such as cell death and protein synthesis.

Research has shown that TRIM34 is involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease. Beta-amyloid plaques are composed of aggregated amyloid peptides, which are thought to contribute to the formation of neurofibrillary tangles and the damage caused by these tangles.

In addition to its role in the formation of beta-amyloid plaques, TRIM34 has also been shown to be involved in the regulation of neurofibrillary tangles. Neurofibrillary tangles are composed of disrupted protein fibers that are thought to contribute to the damage caused by beta-amyloid plaques.

Targeting TRIM34 using drugs that interfere with its activity could potentially slow the progression of Alzheimer's disease by reducing the formation of beta-amyloid plaques and neurofibrillary tangles. This could be an effective way to treat the disease and could provide hope to those who are currently diagnosed with Alzheimer's disease.

While further research is needed to fully understand the role of TRIM34 in Alzheimer's disease, its potential as a drug target and biomarker is an exciting area of study. If TRIM34 is indeed involved in the formation of beta-amyloid plaques and neurofibrillary tangles, it may be possible to develop drugs that specifically target this protein to treat Alzheimer's disease.

In conclusion, TRIM34 is a protein that has been identified as a potential drug target and biomarker for Alzheimer's disease. Its role in the formation of beta-amyloid plaques and neurofibrillary tangles makes it an attractive target for researchers to investigate further. Further research is needed to fully understand the effects of TRIM34 on the progression of Alzheimer's disease, and to develop effective treatments.

Protein Name: Tripartite Motif Containing 34

Functions: Functions as antiviral protein and contributes to the defense against retroviral infections (PubMed:17156811, PubMed:32282853). Acts as a capsid-specific restriction factor with the help of TRIM5 and prevents infection from non-host-adapted retroviruses (PubMed:32282853). During influenza A virus infection, promotes programmed cell death by targeting ZBP1 for 'Lys-63'-linked polyubiquitination (PubMed:35065966). In turn, promotes ZBP1 recruitment of RIPK3 to mediate virus-induced programmed necrosis (PubMed:35065966). Negatively regulates the function of mitochondria by enhancing mitochondrial depolarization leading to cytochrome c release and mitochondria-dependent apoptosis (PubMed:31956709). Promotes also the formation of multinucleated giant cells by means of cell fusion and phagocytosis in epithelial cells (PubMed:31487507)

The "TRIM34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets